|Day Low/High||3.15 / 3.51|
|52 Wk Low/High||2.91 / 11.20|
-- Company to capitalize on proprietary self-delivering RNAi platform (sd-rxRNA®) that has now been proven to be safe and effective in clinical trials
- RXI-109 is a self-delivering RNAi (sd-rxRNA) compound that targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation, and plays a key role in tissue regeneration and repair.
- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharmaceuticals will be explored preclinically
The Center for Cancer Immune Therapy at Herlev Hospital, University of Copenhagen, is a leading European cancer center that received a Global Excellence Award in 2013 from the Capital Region of Denmark
RXI-231 is a cosmetic ingredient in a proprietary gel formulation designed to aid in the reduction of pigmentation to improve skin appearance
Dr. James Cardia, RXi's Director of Business Development and Intellectual Property, will take over the management of the Company's ongoing business development and partnering initiatives
RXi Pharmaceuticals is a collaborator on this grant and will receive a portion of the allotted funding for the development of sd-rxRNA therapeutic compounds targeting PTEN
The forum brings together leading family offices, high net worth private investors, pharma and foundations to explore the latest innovations transforming healthcare.
Study RXI-109-1501 is evaluating the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases
RXI-231 is in development as a cosmetic ingredient that may improve the appearance of uneven skin tone and pigmentation
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.